Abeona Therapeutics(ABEO)

Focus: Abeona Therapeutics is a public biotech company focused on gene therapies and cell therapies for rare genetic diseases, including Sanfilippo syndrome, epidermolysis bullosa, and mucopolysaccharidosis. With 1,001–5,000 employees based in Cleveland, OH, the company operates at mid-cap biotech scale.

Profile data last refreshed 3h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

1001-5000

Open Jobs

Should You Work at Abeona Therapeutics?

AI assessment

Abeona offers compelling rare-disease science and equity upside, but severe cash burn and minimal hiring make it a high-risk, high-reward play suited only for researchers comfortable with startup volatility in a biotech that may need restructuring within 18 months.

Why Work Here

Rare disease focus in high-unmet-need areas (gene therapy for lysosomal storage disorders, cell therapy for epidermolysis bullosa) attracts mission-driven researchers

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$6M

Pipeline & Clinical Trials

ABO-101

Mucopolysaccharidosis III-B

N/A

Clinical Trials (1)

NCT04655911A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

N/A

Help build intelligence for Abeona Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Active pipeline with 11 total trials including multiple Phase 3 programs (EB-101, MSI-78) offering near-term regulatory catalysts and publication opportunity

Public company status provides equity upside for new hires: recent hiring announcements show stock awards covering up to 7,200 shares over 3-year vesting

Watch Out For

Severe cash burn: FY2025 net loss of $63.7M against only $6M revenue, with cash position of $23M indicating urgent need for capital raise or major partnering within 12–18 months
Minimal hiring momentum: only 2 active job openings despite 1,000+ headcount signals potential hiring freeze or restructuring risk as cash depletes
Extremely high R&D intensity (590%) and pre-commercial stage mean job security depends entirely on clinical trial success; any Phase 3 failure could trigger layoffs

Generated by Claude from Abeona Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Prademagene Zamikeracel

Recessive Dystrophic Epidermolysis Bullosa

N/A

Clinical Trials (2)

NCT07717736Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds

Phase 4

NCT07700966A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

N/A

ABO-102

MPS IIIA

Phase 1/2

rAAV9.CMV.hNAGLU

Mucopolysaccharidosis Type 3 B

Phase 1/2

Clinical Trials (1)

NCT03315182Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB

Phase 1/2

Collagen VII (COL7A1 gene transfer)

Recessive Dystrophic Epidermolysis Bullosa

Phase 1/2

NAGLU gene transfer

Mucopolysaccharidosis Type III B

Phase 1/2

LZRSE-Col7A1 Engineered Autologous Epidermal Sheets

Epidermolysis Bullosa Dystrophica

Phase 1/2

Clinical Trials (1)

NCT01263379Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

Phase 1/2

econazole

Onychomycosis

Phase 2

Clinical Trials (1)

NCT00385502A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail

Phase 2

UX111

MPS IIIA

Phase 2/3

EB-101

Recessive Dystrophic Epidermolysis Bullosa

Phase 3

Clinical Trials (3)

NCT05725018A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

Phase 3

NCT04227106Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Phase 3

NCT05708677A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

N/A

MSI-78

Diabetic Foot Ulcers

Phase 3

Clinical Trials (2)

NCT00563394MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Phase 3

NCT00563433MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Phase 3

Interview Prep Quick Facts

Portfolio: 11 clinical trials

Publications: 9 in PubMed

SEC Filings: 2 available

Open Roles: 2 active jobs

Financials (FY2025)

Revenue

$6M66%

R&D Spend

$34M(590%)11%

Net Income

-$64M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(9)

Recent peer-reviewed publications with author affiliations at this company

Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.

Lancet (London, England)

2025

PMID:40570869

Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.